Director Declaration

    January 4, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
    that Ian Clark, Non-Executive Director of the Company, was appointed to the
    Boards of Directors of Agios Pharmaceuticals, Inc. and Corvus Pharmaceuticals,
    Inc. on January 3, 2017.

    This notification is to satisfy the Company's obligations under LR 9.6.14R of
    the UK Listing Rules.

    Oliver Strawbridge
    Senior Assistant Company Secretary

    For further information please contact:

    Investor Relations                                                           
                                                                                 
    Ian Karp                        ikarp@shire.com            +1 781 482 9018   
                                                                                 
    Robert Coates                   rcoates@shire.com          +44 1256 894874   
                                                                                 
    Media                                                                        
                                                                                 
    Lisa Adler                      lisa.adler@shire.com       +1 617 588 8607   
                                                                                 
    Debbi Ford                      debbi.ford@shire.com       +1 617 949 9083   

    NOTES TO EDITORS

    About Shire

    Shire is the leading global biotechnology company focused on serving people
    with rare diseases and other highly specialized conditions. We strive to
    develop best-in-class products, many of which are available in more than 100
    countries, across core therapeutic areas including Hematology, Immunology,
    Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
    Internal Medicine / Endocrine and Hereditary Angioedema; and a growing
    franchise in Oncology.

    Our employees come to work every day with a shared mission: to develop and
    deliver breakthrough therapies for the hundreds of millions of people in the
    world affected by rare diseases and other high-need conditions, and who lack
    effective therapies to live their lives to the fullest.

    www.shire.com